Collegium Pharmaceutical Inc — Liquidità Trimestrale (NASDAQ:COLL) | MetaTrader

Apri il grafico completo

Financials

Panoramica Estratto Conto Statistiche

Trimestrale Annuale

Totale attivo 1.66 B1.63 B1.59 B1.61 B1.66 B Totale passività 1.43 B1.4 B1.36 B1.33 B1.36 B Patrimonio netto totale 228.84 M234.43 M232.21 M274.81 M301.68 M Totale passività e patrimonio netto 1.66 B1.63 B1.59 B1.61 B1.66 B Debito totale 852.49 M837.71 M822.92 M808.12 M809.33 M Indebitamento netto 595.53 M538.35 M495.96 M382.51 M267.22 M

Notizie

Collegium Pharmaceutical, Inc. (COLL) Discusses Acquisition of AZSTARYS to Expand ADHD Portfolio and Accelerate Growth - Slideshow (NASDAQ:COLL) 2026-03-24

Collegium Pharmaceuticals: Another M&A Episode Adds To An Intriguing Case (NASDAQ:COLL)

Collegium Pharmaceutical, Inc. (COLL) Discusses Acquisition of AZSTARYS to Expand ADHD Portfolio and Accelerate Growth Transcript

Jefferies conferma il rating Buy su Collegium Pharmaceutical dopo l’accordo ADHD

Barclays conferma il rating Overweight su Collegium Pharmaceutical

Collegium Pharmaceutical acquisirà AZSTARYS per 650 milioni di dollari

Collegium Pharmaceutical, Inc. 2025 Q4 - Results - Earnings Call Presentation (NASDAQ:COLL) 2026-03-01

Collegium Pharmaceutical (COLL) Reports Q4 Earnings: What Key Metrics Have to Say

Collegium Pharmaceutical (COLL) Q4 Earnings and Revenues Miss Estimates

Collegium Q4 2025: farmaco ADHD in crescita nonostante utili sotto attese

Collegium Q4 2025 slides: ADHD drug surges despite earnings miss

Gli EPS di Collegium Pharmaceutical hanno mancato le aspettative per 0,10$, il fatturato appena sotto le previsioni